We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Deletion Mutation Linked to Prostate Cancer

By Biotechdaily staff writers
Posted on 24 Sep 2002
Investigators have found that a deletion mutation on the MSR1 (macrophage scavenger receptor 1) gene is linked to the likelihood of men of both African-American and European ancestry to develop prostate cancer. More...
The finding was reported in the September 16, 2002, issue of Nature Genetics.

In a collaborative effort, researchers from Johns Hopkins University (Baltimore, MD, USA) and Wake Forest University (Winston-Salem, NC, www.wfu.edu) evaluated the role of MSR1 in a large number of subjects from multiple populations. Initially, eight mutations in MSR1 were found in 159 patients from families that averaged five or more men with prostate cancer. Ultimately they found mutations in 4.4% of Caucasians who had prostate cancer, compared to 0.8% of those found negative in prostate cancer screening. A different mutation of the gene was found in 12.5% of African-American men with prostate cancer, compared to 1.82% of unaffected men.

Both differences were statistically highly significant. "One of the mutations leads to prostate cancer that has rapid metastasis,” said the study's first author, Dr. Jianfeng Xu, associate professor at Wake Forest University. "We provide novel genetic evidence that MSR1 may play an important role in prostate cancer susceptibility.”

Just as there are a number of breast cancer genes, the MSR1 gene probably will turn out to be one of a number of genes linked to prostate cancer. However, the authors suggest that MSR1 shows the strongest gene linkage to inherited prostate cancer risk thus far.




Related Links:
Johns Hopkins University
Wake Forest University

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.